Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 167

Sort by

Sort Order Select

Journal Articles

Costs per Treatment Phase for AML Patients Receiving High-Dose Chemoterapy in Sweden

Emma Hernlund, PhD, Josefine Redig, MSc, Åsa Rangert Derolf, MD PhD, Bjorn Paulsson, MD, Martin Höglund, MD PhD, Simona Vertuani, PhD, Gunnar Juliusson, MD PhD

Blood (2019) 134 (Supplement_1): 2154.

https://doi.org/10.1182/blood-2019-127957

Published: 2019

Journal Articles

Quantifying the Economic Burden of Myelodysplastic Syndromes Among Elderly US Patients

Jason Shafrin, PhD, Sarah Green, BA, Richard Murphy, BA, Katie Everson, MS, Syvart Dennen, M.Phil, Kwanza Price, MPH, Katharine Batt, MD MSc

Blood (2019) 134 (Supplement_1): 2151.

https://doi.org/10.1182/blood-2019-124216

Published: 2019

Journal Articles

Health Economic Burden and Treatment-Based Survival for Current Follicular Lymphoma Treatment Practice in Japan Using a Nationwide Retrospective Claims Database

Saaya Tsutsue, Kensei Tobinai, MD PhD, Jingbo Yi, MPH, Bruce Crawford, MA,MPH

Blood (2019) 134 (Supplement_1): 2129.

https://doi.org/10.1182/blood-2019-122639

Published: 2019

Journal Articles

Systematic Literature Review of the Economic Burden and Cost of Illness in Patients with Myelofibrosis

Derek Tang, PhD BSPharm, Ankush Taneja, Preety Rajora, Renu Patel

Blood (2019) 134 (Supplement_1): 2184.

https://doi.org/10.1182/blood-2019-122919

Published: 2019

Journal Articles

On-Line Patient Portal Use By Caregivers in Pediatric Oncology: Are We Widening Sociodemographic Disparities?

Corinna L Schultz, MD, Suzanne M McCahan, PhD, H. Timothy Bunnell, PhD, Fang Fang Chen, PhD, Melissa A Alderfer, PhD

Blood (2019) 134 (Supplement_1): 2131.

https://doi.org/10.1182/blood-2019-131543

Published: 2019

Journal Articles

The Economic and Health Utilization Cost of Clinically Significant Cytomegalovirus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation

Michelle K Yong, MBBS, FRACP, MPH, PhD, Shio Yen Tio, MBBS, FRACP, Jake Valentine, BBioMedSc, Joe Sasadeusz, MBBS FRACP PhD, Lynette C.Y. Chee, Ashish Bajel, MBBS, FRACP, FRCPA, David Ritchie, MD PhD, Monica Slavin, MBBS FRACP

Blood (2019) 134 (Supplement_1): 3437.

https://doi.org/10.1182/blood-2019-128227

Published: 2019

Journal Articles

Economic Burden of Bronchiolitis Obliterans Syndrome (BOS) Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients with Commercial Insurance in the United States

Naomi Sacks, PhD, Bridget Healey, MPH, Philip Cyr, MPH, Katharine Batt, MD MSc, Noreen Roth Henig, MD

Blood (2019) 134 (Supplement_1): 3410.

https://doi.org/10.1182/blood-2019-127197

Published: 2019

Journal Articles

Economic Burden of Multiple Myeloma: Results from a Large Employer-Sponsored Real-World Administrative Claims Database, 2012 to 2018

Dao Tran, Rajesh Kamalakar, MS, Shivaji Manthena, Sudeep Karve, PhD

Blood (2019) 134 (Supplement_1): 3414.

https://doi.org/10.1182/blood-2019-131264

Published: 2019

Journal Articles

A Pilot Adult Sickle Cell Hematology Clinic in California's Inland Empire Improves Patient Outcome

Neha Chiruvolu, DO, Amie Patel, DO, Carolyn Rowley, PhD, Marsha J. Treadwell, PhD, Elliott P. Vichinsky, MD, Zahra Pakbaz, MD

Blood (2019) 134 (Supplement_1): 3470.

https://doi.org/10.1182/blood-2019-125160

Published: 2019

Journal Articles

Nutrition Access in Adult Sickle Cell Patients: An Exploratory Study

Sarah Agamah, MBA, MPH

Blood (2019) 134 (Supplement_1): 3472.

https://doi.org/10.1182/blood-2019-130505

Published: 2019

Journal Articles

Estimation of the Economic Burden Associated with Major Surgery Due to Von Willebrand Disease Based on Claims Data from the USA

Abiola Oladapo, Yanyu Wu, Mei Lu, Sepehr Farahbakhshian, Bruce Ewenstein

Blood (2019) 134 (Supplement_1): 4692.

https://doi.org/10.1182/blood-2019-122749

Published: 2019

Journal Articles

Optimizing the Economic Impact of Sickle Cell Hospitalization By Effective Care Plans

Bilawal Ahmed, MD, Kelton R Clements, Jonathan Heidt, MD, Michael Trendle, MD, Sindhu Singh, MD

Blood (2019) 134 (Supplement_1): 1023.

https://doi.org/10.1182/blood-2019-129732

Published: 2019

Journal Articles

Successful Transition from Bortezomib Subcutaneous (SubQ) to Generic Intravenous (IV) Bortezomib: Cost Savings Initiative with Global Economic Impact

Radhika Jhaveri, PharmD, Vaishali Sanchorawala, MD, John Mark Sloan, MD, Adam Lerner, MD, Shayna Sarosiek, Bhavesh Shah, RPh

Blood (2019) 134 (Supplement_1): 4758.

https://doi.org/10.1182/blood-2019-128992

Published: 2019

Journal Articles

Economic Burden of Emergency Room (ER) Visits and Hospitalizations Among Newly Diagnosed Multiple Myeloma (NDMM) Patients in the United States

Eric M Maiese, PhD, Xinmei Zhu, PhD, Bingcao Wu, Yen-Wen Chen, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 4715.

https://doi.org/10.1182/blood-2019-127071

Published: 2019

Journal Articles

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Michael S Broder, MD MSHS, Qiufei Ma, PhD, Tingjian Yan, PhD, Eunice Chang, PhD, Lamis K. Eldjerou, MD, Yanni Hao, PhD, David Kuzan, MD, Jie Zhang, PhD

Blood (2019) 134 (Supplement_1): 4719.

https://doi.org/10.1182/blood-2019-122587

Published: 2019

Journal Articles

Overall Survival, Adverse Events, and Economic Burden in Medicare Patients with Chronic Lymphocytic Leukemia Receiving Cancer-Directed Therapy

Ravi K Goyal, MS, Saurabh P Nagar, MS, Shaum M Kabadi, PhD MPH, Keith L Davis, MA, Hannah Le, PharmD, MPH, James A Kaye, MD

Blood (2019) 134 (Supplement_1): 796.

https://doi.org/10.1182/blood-2019-122842

Published: 2019

Journal Articles

Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy

Shaum M Kabadi, PhD MPH, Ravi K Goyal, MS, Saurabh P Nagar, MS, Keith L Davis, MA, Hannah Le, PharmD, MPH, Xianglin L Du, MB, MS, PhD, Preetesh Jain, MBBS,MDDM,PhD, Michael L. Wang, MD, Jorge Enrique Romaguera, MD, James A Kaye, MD

Blood (2019) 134 (Supplement_1): 63.

https://doi.org/10.1182/blood-2019-122841

Published: 2019

Journal Articles

Changing the Fate of Children with Acute Lymphoblastic Leukemia (ALL) in a Limited Resources Setting

Yajaira Valentine Jimenez-Antolinez, MD, Julia Esther Colunga Pedraza, MD, José Eduardo Mares-Gil, MD, Emma Lizeth Estrada, MD, Jesus Mauricio Gonzalez-Diaz, David Gomez-Almaguer, MD, Oscar Gonzalez Llano, MD

Blood (2019) 134 (Supplement_1): 5075.

https://doi.org/10.1182/blood-2019-132205

Published: 2019

Journal Articles

Response to First-Line Treatment in Patients with N/K T-Cell Lymphoma. Experience of a Third Level Mexican Institute

Katheryn Betsabe Garzón, MD, Silvia Rivas-Vera, MD, Brenda L. Acosta-Maldonado, MD

Blood (2019) 134 (Supplement_1): 5286.

https://doi.org/10.1182/blood-2019-129887

Published: 2019

Journal Articles

The Economic Burden of Short-Term Adverse Events Associated with the CHOP Chemotherapy Regimen in Patients with Lymphoproliferative Disorders in the United States: A Comprehensive Literature Review

Crystal Watson, MS, Arie Barlev, PharmD, Jodie Worrall, Steve Duff, MS, Rachel Beckerman, PhD

Blood (2019) 134 (Supplement_1): 5826.

https://doi.org/10.1182/blood-2019-122611

Published: 2019

NARROW

Costs per Treatment Phase for AML Patients Receiving High-Dose Chemoterapy in Sweden

Quantifying the Economic Burden of Myelodysplastic Syndromes Among Elderly US Patients

Health Economic Burden and Treatment-Based Survival for Current Follicular Lymphoma Treatment Practice in Japan Using a Nationwide Retrospective Claims Database

Systematic Literature Review of the Economic Burden and Cost of Illness in Patients with Myelofibrosis

On-Line Patient Portal Use By Caregivers in Pediatric Oncology: Are We Widening Sociodemographic Disparities?

The Economic and Health Utilization Cost of Clinically Significant Cytomegalovirus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation

Economic Burden of Bronchiolitis Obliterans Syndrome (BOS) Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients with Commercial Insurance in the United States

Economic Burden of Multiple Myeloma: Results from a Large Employer-Sponsored Real-World Administrative Claims Database, 2012 to 2018

A Pilot Adult Sickle Cell Hematology Clinic in California's Inland Empire Improves Patient Outcome

Nutrition Access in Adult Sickle Cell Patients: An Exploratory Study

Estimation of the Economic Burden Associated with Major Surgery Due to Von Willebrand Disease Based on Claims Data from the USA

Optimizing the Economic Impact of Sickle Cell Hospitalization By Effective Care Plans

Successful Transition from Bortezomib Subcutaneous (SubQ) to Generic Intravenous (IV) Bortezomib: Cost Savings Initiative with Global Economic Impact

Economic Burden of Emergency Room (ER) Visits and Hospitalizations Among Newly Diagnosed Multiple Myeloma (NDMM) Patients in the United States

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Overall Survival, Adverse Events, and Economic Burden in Medicare Patients with Chronic Lymphocytic Leukemia Receiving Cancer-Directed Therapy

Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy

Changing the Fate of Children with Acute Lymphoblastic Leukemia (ALL) in a Limited Resources Setting

Response to First-Line Treatment in Patients with N/K T-Cell Lymphoma. Experience of a Third Level Mexican Institute

The Economic Burden of Short-Term Adverse Events Associated with the CHOP Chemotherapy Regimen in Patients with Lymphoproliferative Disorders in the United States: A Comprehensive Literature Review

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only